Navigation Links
Genmab's Financial Calendar for 2008
Date:1/31/2008

COPENHAGEN, Denmark, January 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announces its financial calendar for 2008 as follows:

EVENT DATE

Publication of the Annual Report for 2007 Monday, March 31, 2008

Annual General Meeting 2008 Wednesday, April 23, 2008

Publication of the Interim Report for the Wednesday, May 28, 2008

first quarter 2008

Publication of the Interim Report for the Wednesday, August 27, 2008

first half 2008

Publication of the Interim Report for the Wednesday, October 29, 2008

first nine months 2008

Publication of the financial reports will be after market close on the date of the event.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
2. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
3. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
4. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
5. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
6. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
7. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
8. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... Jessica Torrente, Assistant Professor of Radiolog...n Washington, D.C., demonstrated the integration a...clinical practice as an adjunct imaging modality f...ual meeting of the Radiological Society of North A...as to demonstrate how BSGI is used in the clinical...
(Date:11/30/2009)...FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq...dministration (FDA) has granted orphan drug design...dine phosphate, for the rare autoimmune disease La...as previously received orphan drug designation in ... Medicinal Products for Human Use of the European ...
(Date:11/30/2009)...RNewswire/ -- Exiqon A/S (NASDAQ OMX Copenhagen: "...ool ICCB-Longwood Screening Facility (ICCB-L) has ...Excellence. ICCB-L supports investigators at Harv...nstitutions, for high-throughput screening of smal... a novel class of small, non-coding RNA species, w...
(Date:11/30/2009)...DAM, November 30 Elsevie...dical and technical products and services,today a...nsive biomedical,database which holds over 20 mill...eer reviewed journals. , Embase has long ...ical,and pharmaceutical insights. Now, new develop...
Breaking Biology Technology:Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3
... a provider of long-term care services in New Eng...Wendy LaBate has been promoted to Senior Vice Pres...r new position, LaBate will be responsible for pro...Genesis, Regional Vice Presidents of Operations an... center operations, improve efficiencies and promo...
...q: CEPH ) announced today that Sarma P. Duddu, P...ce President of Drug Delivery Technologies of CIMA... aspects of the Cephalon drug delivery business at...ocated in suburban Minnesota. , , (Photo: htt... ) , , In his new role, Dr. Duddu will be a membe...
... Institute Pharma,(TI Pharma) has formed a consort...y Medical Centre and Nobilon, a subsidiary of Sch...ine against the Chikungunya virus. This,vaccine ai... Viral disease epidemics have increased in inc...these diseases is caused by the Chikungunya virus,...
Other Biology Technology:Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 3Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 4Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership 2
(Date:11/30/2009)...ratures continue to rise scientists are presented ...ecies respond and adapt. In a paper published in ...odriguez-Trelles and Dr Miguel Rodriguez assess th... of approximately 0.6˚C has already affected ...ng ecologists and evolutionary biologists is to pr...
(Date:11/30/2009)...report published in the December 2009 print issue ...lar type of control over their fertility that wome...sts have found how and where androgenic hormones w...on and male fertility. This opens a promising aven...discovery also offers hope to those who cannot hav...
(Date:11/26/2009)...r impressive antlers, red deer have been caught in... antlers are much more than decorative. They are l...ing. John Currey, from The University of York, UK,...f bone for over half a century and has become fasc...ugh a long-standing collaboration with Tomas Lande...
Breaking Biology News(10 mins):How can scientists measure evolutionary responses to climate change? 2Tough yet stiff deer antler is materials scientist's dream 2Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 1Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 2Hologic to Present at the 29th Annual Canaccord Adams Global Growth Conference 51475 1Hush little baby Linking genes brain and behavior in children 9237 1Hush little baby Linking genes brain and behavior in children 9237 2
... New knowledge points to the fact that a genetical... skin barrier, plays a decisive role in the origin...school-children scientists of the Helmholtz Zentru...d that about 8% of the German population carry var...k to develop atopic dermatitis more than threefold...
... Measures for better air , Now that Olympia is ap...educe the air pollution in the large cities with d... Beijing is massively limited: the government has ... Private cars are only allowed to drive on even or...number. Furthermore, legal regulations have been i...
... PHILADELPHIA Based on a pilot study in children ...es of Health (NIH) believe that immunotherapy coul...this cancer. , The researchers tested a novel de...to potentially strengthen the immune system post c...ust 1 issue of Clinical Cancer Research , a journ...
Other Biology News:When our protective armor shows weakness 2GKSS membranes reduce air pollution in Beijing 2Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
...ost comprehensive, cost-effective solution to your...ated unprecedented quality into both our products ...ection chemistries and antibodies that have been o...s our competitively priced accessories that can be...
Mouse Anti-Yellow Fever Virus Monoclonal Antibody, Unconjugated, Clone 3576 from Abcam
Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Gel Loading Dye (Bromophenol Blue/Glycerol) from Mo Bio Laboratories, Inc.
Biology Products: